How Past Stigma and Recreational Use Are Slowing Psychedelic Science

According to recent research conducted in America that involved 952 individuals, psychedelic researchers who admitted to using psychedelic substances are often viewed by their abstinent counterparts as having less integrity. The study, which was reported in the “Public Understanding of Science” journal, proposes that stereotypes about both psychedelics and the individuals who use them may affect an individual’s view of researchers.

University of Zurich’s Matthias Forstmann, who is the one of the authors of the study, stated that the personal use of these substances by the scientists studying them was a common occurrence, although very few researchers were open about it. He went on to explain that many researchers publicize their association with the psychedelics field, despite knowing next to nothing about how such public associations and admissions impact the public’s view of the research being conducted by these scientists.

In the first two studies, participants read a short story about a researcher who was carrying out research on psychedelic substances. The scientists discovered that after the story disclosed that the researcher had comprehensive personal experience with ingesting psychedelics, the participants perceived the researcher as possessing less scientific integrity, in comparison with when the story mentioned that the researcher had no personal experience with the psychedelic substances.

During the third study, participants were required to assess the quality of research that was being presented at a conference on the “science of psychedelics.” The participants described the conference as either comprising of normal social activities, such as a local brewery tour, or including social activities that were related to psychedelics, such as a group meditation session.

Along with assessing the research quality, participants were also shown pictures of both versions of the conference, with pictures of the former version of the conference showing it took place in a typical university auditorium and the latter in a spacious hall that had colorful light installations.

Researchers found that the participants perceived the research quality at the conference to be lower when it was inclusive of psychedelic imagery and activities. The study’s findings indicate that being linked to the psychedelic subculture or admitting to the personal use of psychedelics could negatively influence the public’s view of a researcher’s work with regard to the validity of that work as well as the integrity of the researcher.

Study authors Christina Sagioglou and Matthias Forstmann noted that additional research was required to learn more about the processes that made up the basis for the effects they observed in the study.

Those perceptions notwithstanding, many companies are pressing ahead with R&D in the psychedelics sector. An example is XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which has invested its bioscience acceleration efforts on developing psychedelic medicines.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050